The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Self-citationGraham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
Talpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,019
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Self-citationBranford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., Seymour, J. F., Arthur, C., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2896 · Cited by 765
Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Mahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 584
Thomas, D. A. (2004) · Blood · doi:10.1182/blood-2003-08-2958 · Cited by 571
van der Velden, V. H. J., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., & van Dongen, J. J. M. (2003) · Leukemia · doi:10.1038/sj.leu.2402922 · Cited by 563
Self-citationOttmann, O. G. (2002) · Blood · doi:10.1182/blood-2001-12-0181 · Cited by 555
Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D. S., Sawyers, C. L., Arber, D. A., Slovak, M. L., & Forman, S. J. (2003) · Blood · doi:10.1182/blood-2002-09-2780 · Cited by 547
Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Laı̈, J.-L., Philippe, N., Facon, T., Fenaux, P., & Preudhomme, C. (2002) · Blood · doi:10.1182/blood.v100.3.1014 · Cited by 515
von Bubnoff, N., Schneller, F., Peschel, C., & Duyster, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 464
Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Giles, F., Rios, M. B., Shan, J., Letvak, L., Thomas, D., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3800 · Cited by 392
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R., & Scapozza, L. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)00979-3 · Cited by 373
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Deininger, M. W. N., & Druker, B. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.4 · Cited by 365
Thiesing, J. T., Ohno-Jones, S., Kolibaba, K. S., & Druker, B. J. (2000) · Blood · doi:10.1182/blood.v96.9.3195 · Cited by 309
Illmer, T., Schaich, M., Platzbecker, U., Freiberg-Richter, J., Oelschlägel, U., von Bonin, M., Pursche, S., Bergemann, T., Ehninger, G., & Schleyer, E. (2004) · Leukemia · doi:10.1038/sj.leu.2403257 · Cited by 307
Kantarjian, H. M., Talpaz, M., O'Brien, S., Giles, F., Garcia-Manero, G., Faderl, S., Thomas, D., Shan, J., Rios, M. B., & Cortes, J. (2003) · Blood · doi:10.1182/blood-2002-05-1451 · Cited by 306
Roots of Clinical Resistance to STI-571 Cancer Therapy
Barthe, C., Cony-Makhoul, P., Melo, J. V., & Mahon, J. R. F.-X. (2001) · Science · doi:10.1126/science.293.5538.2163a · Cited by 271
Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y., Honma, Y., & Furukawa, Y. (2001) · Blood · doi:10.1182/blood.v97.7.1999 · Cited by 262
Corbin, A. S., Rosée, P. L., Stoffregen, E. P., Druker, B. J., & Deininger, M. W. (2003) · Blood · doi:10.1182/blood-2002-12-3659 · Cited by 258
ARG tyrosine kinase activity is inhibited by STI571
Okuda, K., Weisberg, E., Gilliland, D. G., & Griffin, J. D. (2001) · Blood · doi:10.1182/blood.v97.8.2440 · Cited by 257
Roumiantsev, S., Shah, N. P., Gorre, M. E., Nicoll, J., Brasher, B. B., Sawyers, C. L., & Van Etten, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162140299 · Cited by 253
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
Hoover, R. R., Mahon, F.-X., Melo, J. V., & Daley, G. Q. (2002) · Blood · doi:10.1182/blood.v100.3.1068 · Cited by 241
Hofmann, W.-K., Jones, L. C., Lemp, N. A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O. G., & Koeffler, H. P. (2002) · Blood · doi:10.1182/blood.v99.5.1860 · Cited by 239
Cortes, J. E., Talpaz, M., Giles, F., O'Brien, S., Rios, M. B., Shan, J., Garcia-Manero, G., Faderl, S., Thomas, D. A., Wierda, W., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2790 · Cited by 236
Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N., & Sawyers, C. L. (2002) · Blood · doi:10.1182/blood-2002-05-1361 · Cited by 227
Gambacorti-Passerini, C. B., Zucchetti, M., Russo, D., Frapolli, R., Verga, M., Bungaro, S., Tornaghi, L., Rossi, F., Pioltelli, P. E., Pogliani, E., et al. (2003) · PubMed · Cited by 226
Bumm, T., Müller, C., Al-Ali, H.-K., Krohn, K., Shepherd, P., Schmidt, E., Leiblein, S., Franke, C., Hennig, E., Friedrich, T., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2053 · Cited by 221
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
Cathcart, K., Pinilla-Ibarz, J., Korontsvit, T., Schwartz, J., Zakhaleva, V., Papadopoulos, E. B., & Scheinberg, D. A. (2004) · Blood · doi:10.1182/blood-2003-03-0954 · Cited by 208
Melo, J. V., Hughes, T. P., & Apperley, J. F. (2003) · Hematology · doi:10.1182/asheducation-2003.1.132 · Cited by 204
Mechanisms and implications of imatinib resistance mutations in BCR-ABL
Nardi, V., Azam, M., & Daley, G. Q. (2004) · Current Opinion in Hematology · doi:10.1097/00062752-200401000-00006 · Cited by 191
Cortes, J., Giles, F., O'Brien, S., Thomas, D., Garcia-Manero, G., Rios, M. B., Faderl, S., Verstovsek, S., Ferrajoli, A., Freireich, E. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0025 · Cited by 188
Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia
ten Hoeve, J., Arlinghaus, R., Guo, J., Heisterkamp, N., & Groffen, J. (1994) · Blood · doi:10.1182/blood.v84.6.1731.1731 · Cited by 183
Peters, D. G., Hoover, R. R., Gerlach, M. J., Koh, E. Y., Zhang, H., Choe, K., Kirschmeier, P., Bishop, W. R., & Daley, G. Q. (2001) · Blood · doi:10.1182/blood.v97.5.1404 · Cited by 173
Topaly, J., Zeller, W., & Fruehauf, S. (2001) · Leukemia · doi:10.1038/sj.leu.2402041 · Cited by 170
Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571
Corbin, A. S., Buchdunger, E., Pascal, F., & Druker, B. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111525200 · Cited by 162
Branford, S., Rudzki, Z., Harper, A., Grigg, A., Taylor, K. F., Durrant, S., Arthur, C., Browett, P., Schwarer, A. P., David, D. F., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403158 · Cited by 154
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML
O'Dwyer, M. E., Mauro, M. J., Kurilik, G., Mori, M., Balleisen, S., Olson, S. B., Magenis, E., Capdeville, R., & Druker, B. J. (2002) · Blood · doi:10.1182/blood-2002-03-0777 · Cited by 145
Medina, J., Kantarjian, H., Talpaz, M., O'Brien, S. M., Garcia‐Manero, G., Giles, F. J., Rios, M. B., Hayes, K. J., & Cortes, J. E. (2003) · Cancer · doi:10.1002/cncr.11729 · Cited by 131
Sneed, T. B., Kantarjian, H. M., Talpaz, M., O'Brien, S. M., Rios, M. B., Bekele, B. N., Zhou, X., Resta, D. J., Wierda, W., Faderl, S. H., et al. (2003) · Cancer · doi:10.1002/cncr.11863 · Cited by 127
Müller, M. C., Gattermann, N., Lahaye, T., Deininger, M. W., Berndt, A., Früehauf, S., Neubauer, A., Fischer, T. H., HOSSFELD, D. K., Schneller, F., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403157 · Cited by 124
Self-citationHofmann, W., Komor, M., Waßmann, B., Jones, L. C., Gschaidmeier, H., Hoelzer, D. F., Koeffler, H. P., & Ottmann, O. G. (2003) · Blood · doi:10.1182/blood-2002-06-1756 · Cited by 124
von Bubnoff, N. C. C., Peschel, C., & Duyster, J. (2003) · Leukemia · doi:10.1038/sj.leu.2402889 · Cited by 122
Soverini, S., Martinelli, G., Amabile, M., Poerio, A., Bianchini, M., Rosti, G., Pane, F., Saglio, G. N., Baccarani, M., the Italian Cooperative Study Group on Chronic Myeloid Leukemia (icsg-cml), et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.031112 · Cited by 120
O'Dwyer, M. E., Gatter, K. M., Loriaux, M., Druker, B. J., Olson, S. B., Magenis, R. E., Lawce, H. J., Mauro, M. J., Maziarz, R. T., & Braziel, R. M. (2003) · Leukemia · doi:10.1038/sj.leu.2402848 · Cited by 114
Al‐Ali, H. K., Heinrich, M. C., Lange, T., Krahl, R., Mueller, M., Müller, C., Niederwieser, D. W., Druker, B. J., & Deininger, M. W. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200319 · Cited by 111
Detection and quantification of residual disease in chronic myelogenous leukemia
Hochhaus, A., Weisser, A., Rosée, P. G. L., Emig, M., Muller, M. C., Saußele, S., Reiter, A., Kühn, C., Berger, U., Hehlmann, R., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401811 · Cited by 109
Self-citationRosée, P. G. L., O'Dwyer, M. E., & Druker, B. J. (2002) · Leukemia · doi:10.1038/sj.leu.2402555 · Cited by 104
Marktel, S., Marín, D., Foot, N. J., Szydlo, R., Bua, M., Karadimitris, A., Melo, V. A. S. D., Kotzampaltiris, P., Dazzi, F., Rahemtulla, A., et al. (2003) · PubMed · Cited by 102
Rosée, P. G. L., Johnson, K. J., O'Dwyer, M. E., & Druker, B. J. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00836-6 · Cited by 97
Schoch, C., Haferlach, T., Kern, W., Schnittger, S., Berger, U., Hehlmann, R., Hiddemann, W., & Hochhaus, A. (2003) · Leukemia · doi:10.1038/sj.leu.2402813 · Cited by 95
Self-citationResistance to imatinib (Glivec): update on clinical mechanisms
Weisberg, E., & Griffin, J. D. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00062-1 · Cited by 91
Kreuzer, K. ‐., le Coutre, P., Landt, O., Na, I., Schwarz, M., Schultheis, K., Hochhaus, A., & Dörken, B. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0644-y · Cited by 87
Self-citationLessons learned from the development of imatinib
Lydon, N., & Druker, B. J. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.10.002 · Cited by 77
Cytogenetic and molecular mechanisms of resistance to imatinib
Hochhaus, A. (2003) · Seminars in Hematology · doi:10.1053/shem.2003.50045 · Cited by 75
Self-citationLarghero, J., Leguay, T., Mourah, S., Madelaine, I., Taksin, A., Raffoux, E., Bastie, J.-N., Degos, L., Berthaud, P., Marolleau, J., et al. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00469-6 · Cited by 71
Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography
Deininger, M. W., McGreevey, L. S., Willis, S. G., Bainbridge, T., Druker, B. J., & Heinrich, M. C. (2004) · Leukemia · doi:10.1038/sj.leu.2403307 · Cited by 70
Chronic myeloid leukemia—still a few questions
Goldman, J. M. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2003.10.001 · Cited by 69
le Coutre, P., Kreuzer, K., Na, I., Lupberger, J., Holdhoff, M., Appelt, C., Schwarz, M., Müller, C., Gambacorti-Passerini, C. B., Platzbecker, U., et al. (2002) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2002.0493 · Cited by 67
Gardembas, M., Rousselot, P. H., Tulliez, M., Vigier, M., Buzyn, A., Huguet, F., Legros, L., Michallet, M., Berthou, C., Cheron, N., et al. (2003) · Blood · doi:10.1182/blood-2003-04-1010 · Cited by 63
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Shan, J., Rios, M. B., Faderl, S. H., Verstovšek, S., Garcia‐Manero, G., Wierda, W. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1035-3 · Cited by 61
Bornhäuser, M., Jenke, A., Freiberg‐Richter, J., Radke, J., Schuler, U. S., Mohr, B., Ehninger, G., & Schleyer, E. (2004) · Annals of Hematology · doi:10.1007/s00277-003-0829-4 · Cited by 53
Sureda, A. M., Carrasco, M., de Miguel, M., Martínez, J. A., Conde, E. D. V., Sanz, M. Á., Diaz‐Mediavilla, J., & Sierra, J. (2003) · PubMed · Cited by 48
Kreuzer, K.-A., le Coutre, P., Landt, O., Na, I.-K., Schwarz, M., Schultheis, K., Hochhaus, A., & D�rken, B. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0690-5 · Cited by 48
Self-citationMinimal residual disease in chronic myeloid leukemia
Löwenberg, B. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038130 · Cited by 44
Feldman, E. J., Najfeld, V., Schuster, M. K., Roboz, G. J., Chadburn, A., & Silver, R. T. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00176-0 · Cited by 38
Giles, F. J., Feldman, E. J., Roboz, G. J., Larson, R. A., Mamus, S. W., Cortes, J. E., Verstovšek, S., Faderl, S. H., Talpaz, M., Beran, M., et al. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00094-8 · Cited by 22
Rosée, P. G. L., Shen, L., Stoffregen, E. P., Deininger, M. W., & Druker, B. J. (2003) · The Hematology Journal · doi:10.1038/sj.thj.6200297 · Cited by 18
le Coutre, P., Kreuzer, K., Na, I., Schwarz, M., Lupberger, J., Holdhoff, M., Baskaynak, G., Gschaidmeier, H., Platzbecker, U., Ehninger, G., et al. (2003) · American Journal of Hematology · doi:10.1002/ajh.10364 · Cited by 14
Imatinib Mesylate Noncompliance Simulating Chronic Myeloid Leukemia Resistance
Sandoval, C., Giamelli, J., & Jayabose, S. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200306000-00017 · Cited by 7
Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene
Janssen, J. J. W. M., Hochhaus, A., Oostveen, J. W. V., Waisfisz, Q., Schuurhuis, G. J., & Ossenkoppele, G. J. (2004) · Leukemia · doi:10.1038/sj.leu.2403338 · Cited by 3
Self-citation(2002) · PubMed
Cited by
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Kantarjian, H. M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F.-E., O'Brien, S. G., Litzow, M., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080689 · Cited by 746
Self-citationMolecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás-Cardama, A., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 745
Hehlmann, R., Hochhaus, A., & Baccarani, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61165-9 · Cited by 501
Self-citation
Metadata
- Authors
- Hochhaus, A., & La Rosée, P.
- Venue
- Leukemia
- Published
- 2004-06-24
- Volume
- 18
- Issue
- 8
- Pages
- 1321-1331
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2076736727
- Cited by
- 336
- References
- 85
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.